TABLE 1. Cases of SARS-CoV-2 infections per 1,000 vaccinated and unvaccinated persons — Oregon and Washington, July 4–September 11, 2021.
| Characteristic | Vaccinated persons* |
Unvaccinated persons |
IRR (95% CI)** | ||||
|---|---|---|---|---|---|---|---|
| Total | No. of cases† | Incidence§ (95% CI) | Total | No. of cases† | Incidence¶ (95% CI) | ||
|
Overall
|
344,848 |
3,009 |
8.7 (8.4–9.0) |
137,616 |
4,146 |
30.1 (29.2–31.1) |
3.45 (3.30–3.62) |
|
COVID-19 vaccine manufacturer
| |||||||
| Janssen (Johnson & Johnson) |
19,850 |
303 |
15.3 (13.6–17.1) |
NA |
NA |
NA |
NA |
| Pfizer-BioNTech |
229,216 |
2,083 |
9.1 (8.7–9.5) |
NA |
NA |
NA |
NA |
| Moderna |
95,782 |
623 |
6.5 (6.0–7.0) |
NA |
NA |
NA |
NA |
|
Race/Ethnicity††
| |||||||
| White, NH |
238,489 |
2,155 |
9.0 (8.7–9.4) |
82,308 |
2,824 |
34.3 (33.1–35.6) |
3.80 (3.59–4.01) |
| Hispanic |
25,993 |
349 |
13.4 (12.1–14.9) |
10,856 |
437 |
40.3 (36.7–44.2) |
3.00 (2.61–3.44) |
| Non-White, NH |
41,404 |
293 |
7.1 (6.3–7.9) |
12,636 |
435 |
34.4 (31.3–37.8) |
4.86 (4.20–5.63) |
| Not specified |
38,962 |
212 |
5.4 (4.8–6.2) |
31,816 |
450 |
14.1 (12.9–15.5) |
2.60 (2.21–3.06) |
|
Race
| |||||||
| AI/AN |
1,280 |
18 |
14.1 (8.9–22.3) |
588 |
23 |
39.1 (26.0–58.9) |
2.78 (1.51–5.11) |
| Asian |
22,828 |
111 |
4.9 (4.0–5.9) |
3,930 |
78 |
19.8 (15.9–24.8) |
4.08 (3.06–5.44) |
| Black/AA |
8,224 |
80 |
9.7 (7.8–12.1) |
4,851 |
197 |
40.6 (35.3–46.7) |
4.17 (3.23–5.40) |
| NHPI |
1,931 |
30 |
15.5 (10.9–22.2) |
1,021 |
63 |
61.7 (48.2–79.0) |
3.97 (2.59–6.09) |
| White |
242,110 |
2,193 |
9.1 (8.7–9.4) |
83,474 |
2,862 |
34.3 (33.1–35.6) |
3.79 (3.58–4.00) |
| All other races |
2,142 |
23 |
10.7 (7.1–16.2) |
848 |
26 |
30.7 (20.9–45.0) |
2.86 (1.64–4.98) |
| Multiple races |
7,368 |
59 |
8.0 (6.2–10.3) |
2,054 |
71 |
34.6 (27.4–43.6) |
4.32 (3.07–6.08) |
| Not specified |
58,965 |
495 |
8.4 (7.7–9.2) |
40,850 |
826 |
20.2 (18.9–21.6) |
2.41 (2.16–2.69) |
|
Ethnicity
| |||||||
| Hispanic/Latino |
25,993 |
349 |
13.4 (12.1–14.9) |
10,856 |
437 |
40.3 (36.7–44.2) |
3.00 (2.61–3.44) |
| Not Hispanic/Latino |
278,750 |
2,439 |
8.7 (8.4–9.1) |
93,994 |
3,239 |
34.5 (33.3–35.7) |
3.94 (3.74–4.15) |
| Not specified |
40,105 |
221 |
5.5 (4.8–6.3) |
32,766 |
470 |
14.3 (13.1–15.7) |
2.60 (2.22–3.05) |
|
Sex§§
| |||||||
| Female |
187,711 |
1,710 |
9.1 (8.7–9.6) |
63,841 |
2,074 |
32.5 (31.1–33.9) |
3.57 (3.35–3.80) |
| Male |
156,960 |
1,299 |
8.3 (7.8–8.7) |
73,592 |
2,067 |
28.1 (26.9–29.3) |
3.39 (3.17–3.64) |
|
Age group, yrs
| |||||||
| 12–17 |
15,234 |
48 |
3.2 (2.4–4.2) |
15,179 |
424 |
27.9 (25.4–30.7) |
8.87 (6.58–11.94) |
| 18–24 |
23,576 |
228 |
9.7 (8.5–11.0) |
20,817 |
623 |
29.9 (27.7–32.4) |
3.09 (2.66–3.60) |
| 25–34 |
46,622 |
478 |
10.3 (9.4–11.2) |
27,375 |
903 |
33.0 (30.9–35.2) |
3.22 (2.88–3.59) |
| 35–44 |
56,291 |
540 |
9.6 (8.8–10.4) |
23,341 |
754 |
32.3 (30.1–34.7) |
3.37 (3.02–3.76) |
| 45–54 |
54,978 |
561 |
10.2 (9.4–11.1) |
19,885 |
647 |
32.5 (30.1–35.1) |
3.19 (2.85–3.57) |
| 55–64 |
57,176 |
475 |
8.3 (7.6–9.1) |
17,313 |
481 |
27.8 (25.4–30.4) |
3.34 (2.95–3.79) |
| 65–74 |
56,607 |
420 |
7.4 (6.7–8.2) |
9,148 |
208 |
22.7 (19.8–26.0) |
3.06 (2.60–3.61) |
| ≥75 |
34,364 |
259 |
7.5 (6.7–8.5) |
4,558 |
106 |
23.3 (19.2–28.1) |
3.09 (2.47–3.86) |
| Median age, yrs (range) | 50 (12–104) | 48 (12–101) | NA | 37 (12–104) | 36 (12–100) | NA | NA |
Abbreviations: AA = African American; AI/AN = American Indian or Alaska Native; IRR = incidence rate ratio; NA = not applicable; NH = non-Hispanic; NHPI = Native Hawaiian or Other Pacific Islander.
* Received ≥2 doses of Pfizer-BioNTech or Moderna vaccine or 1 dose of Janssen (Johnson & Johnson) COVID-19 vaccine.
† Positive SARS-CoV-2 molecular test result >14 days after second dose of Pfizer-BioNTech or Moderna vaccine dose or first dose of Janssen COVID-19 vaccine.
§ Cases per 1,000 vaccinated persons.
¶ Cases per 1,000 unvaccinated persons.
** To be more conservative given the large sample size, sensitivity analyses with α levels of 0.01 and 0.005 were conducted, and study findings and conclusions remain unchanged.
†† Persons who self-identified as Hispanic or Latino ethnicity were categorized as Hispanic. Persons who identified as AI/AN, Black, AA, NHPI, multiracial, or any other race were categorized as non-White, NH. The non-White, NH category most commonly included persons who identified as Asian (26,758) or Black (13,075).
§§ Persons of unknown sex (177 vaccinated and 183 unvaccinated) are not represented.